Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches - a PEARRL review.


Journal

The Journal of pharmacy and pharmacology
ISSN: 2042-7158
Titre abrégé: J Pharm Pharmacol
Pays: England
ID NLM: 0376363

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 08 03 2018
accepted: 27 06 2018
pubmed: 3 8 2018
medline: 26 4 2019
entrez: 3 8 2018
Statut: ppublish

Résumé

This review highlights aspects of drug hydrophobicity and lipophilicity as determinants of different oral formulation approaches with specific focus on enabling formulation technologies. An overview is provided on appropriate formulation selection by focussing on the physicochemical properties of the drug. Crystal lattice energy and the octanol-water partitioning behaviour of a poorly soluble drug are conventionally viewed as characteristics of hydrophobicity and lipophilicity, which matter particularly for any dissolution process during manufacturing and regarding drug release in the gastrointestinal tract. Different oral formulation strategies are discussed in the present review, including lipid-based delivery, amorphous solid dispersions, mesoporous silica, nanosuspensions and cyclodextrin formulations. Current literature suggests that selection of formulation approaches in pharmaceutics is still highly dependent on the availability of technological expertise in a company or research group. Encouraging is that, recent advancements point to more structured and scientifically based development approaches. More research is still needed to better link physicochemical drug properties to pharmaceutical formulation design.

Identifiants

pubmed: 30070363
doi: 10.1111/jphp.12984
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

464-482

Subventions

Organisme : H2020 Marie Skłodowska-Curie Actions
ID : 674909

Informations de copyright

© 2018 Royal Pharmaceutical Society.

Auteurs

Felix Ditzinger (F)

Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland.

Daniel J Price (DJ)

Analytics Healthcare, Merck KGaA, Darmstadt, Germany.
Goethe University, Frankfurt, Germany.

Alexandra-Roxana Ilie (AR)

School of Pharmacy, University College Cork, Cork, Ireland.
Drug Product Development, Janssen Research and Development, Johnson and Johnson, Beerse, Belgium.

Niklas J Köhl (NJ)

School of Pharmacy, University College Cork, Cork, Ireland.

Sandra Jankovic (S)

Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland.

Georgia Tsakiridou (G)

Product Design & Evaluation, Pharmathen SA, Athens, Greece.
Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.

Simone Aleandri (S)

Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland.

Lida Kalantzi (L)

Product Design & Evaluation, Pharmathen SA, Athens, Greece.

René Holm (R)

Drug Product Development, Janssen Research and Development, Johnson and Johnson, Beerse, Belgium.

Anita Nair (A)

Analytics Healthcare, Merck KGaA, Darmstadt, Germany.

Christoph Saal (C)

Analytics Healthcare, Merck KGaA, Darmstadt, Germany.

Brendan Griffin (B)

School of Pharmacy, University College Cork, Cork, Ireland.

Martin Kuentz (M)

Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH